J&J projects US$60 Bln in sales x 2025 led by oncology drugs
"During the third quarter, J&J's pharma growth largely came from the oncology and immunology sectors, thanks to Tremfya and Darzalex. Darzalex on its own achieved 38.7% growth worldwide and contributed over $2 billion in revenue during the quarter, setting the multiple myeloma drug up to be a pharmaceutical superstar. Lee Brown, global sector lead for healthcare at Third Bridge, noted the “phenomenal growth” of Darzalex in a series of remarks."
[The "phenomenal growth" in J&J's cancer portfolio demonstrates the trajectory that the whole oncology market is headed - at a time when ONCY's pelareorep is close to approval and which could come very early with an accelerated approval filing by ONCY's eventual acquirer ]
https://www.fiercepharma.com/financials/johnson-johnson-sticks-2025-projection-60-billion-pharma-sales-relying-eight-key-brands